Olema Pharmaceuticals (OLMA) Share-based Compensation (2020 - 2026)
Olema Pharmaceuticals (OLMA) reported Share-based Compensation of $10.1 million for Q1 2026, up 131.8% year-over-year from $4.4 million in Q1 2025, and up 137.88% quarter-over-quarter from $4.3 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Share-based Compensation (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Share-based Compensation data on file, last reported at $10.1 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $10.1 million, up 131.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.4 million (up 5.92% YoY), and the FY2025 annual result was $17.6 million, down 22.12% from the prior year.
- Share-based Compensation advanced to $10.1 million in Q1 2026 per OLMA's latest filing, from $4.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $10.1 million in Q1 2026 and troughed at $4.1 million in Q3 2023.
- A 5-year average of $5.1 million and a median of $4.7 million in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation sank 32.53% in 2025, then jumped 131.8% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $4.9 million in 2022, then declined by 10.49% to $4.4 million in 2023, then soared by 45.32% to $6.3 million in 2024, then slumped by 32.53% to $4.3 million in 2025, then surged by 137.88% to $10.1 million in 2026.
- Business Quant data shows OLMA's Share-based Compensation at $10.1 million in Q1 2026, $4.3 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 26.47 Mn |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - | 10.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.15 Mn |
| Mar 31, 2026 | 10.15 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.25 Mn |
| Sep 30, 2025 | 4.25 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Mar 31, 2025 | 4.38 Mn |
| Mar 31, 2025 | 4.38 Mn |
| Dec 31, 2024 | 6.32 Mn |
| Dec 31, 2024 | 6.32 Mn |
| Sep 30, 2024 | 5.63 Mn |
| Sep 30, 2024 | 5.63 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Mar 31, 2024 | 4.91 Mn |
| Mar 31, 2024 | 4.91 Mn |
| Dec 31, 2023 | 4.35 Mn |
| Dec 31, 2023 | 4.35 Mn |